Ngā hua rapu kaituhi :: APM

1

Application of a Fracture Risk Algorithm to Men Treated With Androgen Deprivation Therapy for Prostate Cancer mā Philip J. Saylor, Donald S. Kaufman, M. Dror Michaelson, Richard J. Lee, Matthew R. Smith

I whakaputaina 2010

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
2

Management of Complications of Prostate Cancer Treatment mā M. Dror Michaelson, S. E. Cotter, Patricio C. Gargollo, Anthony L. Zietman, Douglas M. Dahl, Mitchell R. Smith

I whakaputaina 2008

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
3

Magnetic Resonance Imaging–Measured Blood Flow Change after Antiangiogenic Therapy with PTK787/ZK 222584 Correlates with Clinical Outcome in Metastatic Renal Cell Carcinoma mā C. de Bazelaire, David C. Alsop, Daniel J. George, Iván Pedrosa, Yongyu Wang, M. Dror Michaelson, Neil M. Rofsky

I whakaputaina 2008

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
4

Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-α in a phase III trial: final results and geographical analysis... mā David Cella, M. Dror Michaelson, Andrew G. Bushmakin, Joseph C. Cappelleri, Claudie Charbonneau, S T Kim, J Z Li, Robert J. Motzer

I whakaputaina 2010

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
5

A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC) mā Ana M. Molina, Thomas E. Hutson, James Larkin, Anne Gold, Karen Wood, Dave Carter, Robert J. Motzer, M. Dror Michaelson

I whakaputaina 2013

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
6

Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinom... mā Sujata Patil, Robert A. Figlin, Thomas E. Hutson, M. Dror Michaelson, Sylvie Négrier, S.T. Kim, Xin Huang, Robert J. Motzer

I whakaputaina 2010

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
7

Randomized Controlled Trial of Annual Zoledronic Acid to Prevent Gonadotropin-Releasing Hormone Agonist–Induced Bone Loss in Men With Prostate Cancer mā M. Dror Michaelson, Donald S. Kaufman, Hang Lee, Francis J. McGovern, Philip W. Kantoff, Mary Anne Fallon, Joel S. Finkelstein, Matthew R. Smith

I whakaputaina 2007

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
8

Human Kidney Injury Molecule-1 Is a Tissue and Urinary Tumor Marker of Renal Cell Carcinoma mā Won Kon Han, Anwar Alinani, Chin‐Lee Wu, M. Dror Michaelson, Massimo Loda, Francis J. McGovern, Ravi Thadhani, Joseph V. Bonventre

I whakaputaina 2005

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
9

Phase II study of sunitinib in men with advanced prostate cancer mā M. Dror Michaelson, Meredith M. Regan, William Oh, Donald S. Kaufman, Kara Olivier, Simon Michaelson, Beverly Spicer, Carol Gurski, Philip W. Kantoff, Matthew Smith

I whakaputaina 2009

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
10

$Activity of second‐line chemotherapy in docetaxel‐refractory hormone‐refractory prostate cancer patients$

Activity of second‐line chemotherapy in docetaxel‐refractory hormone‐refractory prostate cancer patients mā Jonathan E. Rosenberg, Vivian Weinberg, William K. Kelly, M. Dror Michaelson, Maha Hussain, George Wilding, Mitchell E. Gross, Douglass Hutcheon, Eric J. Small

I whakaputaina 2007

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
11

Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins mā Samuel E. DePrimo, Carlo L. Bello, John Smeraglia, Charles M. Baum, Dominic G. Spinella, Brian I. Rini, M. Dror Michaelson, Robert J. Motzer

I whakaputaina 2007

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
12

Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients mā Frede Donskov, M. Dror Michaelson, Igor Puzanov, Mellar P. Davis, Georg A. Bjarnason, Robert J. Motzer, David Goldstein, Xun Lin, Darrel P. Cohen, Robin Wiltshire, Brian I. Rini

I whakaputaina 2015

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
13

Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor‐risk metastatic renal cell carcinoma mā M. Dror Michaelson, Rana R. McKay, Lillian Werner, Michael B. Atkins, Eliezer M. Van Allen, Kara Olivier, Jiaxi Song, Sabina Signoretti, David F. McDermott, Toni K. Choueiri

I whakaputaina 2015

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
14

A Dose-Ranging Study of Cabozantinib in Men with Castration-Resistant Prostate Cancer and Bone Metastases mā Richard J. Lee, Philip J. Saylor, M. Dror Michaelson, S. Michael Rothenberg, Malgorzata E. Smas, David T. Miyamoto, Carol Gurski, Wanling Xie, Shyamala Maheswaran, Daniel A. Haber, Jonathan Goldin, Matthew R. Smith

I whakaputaina 2013

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
15

NCCN Task Force Report: Optimizing Treatment of Advanced Renal Cell Carcinoma With Molecular Targeted Therapy mā Gary R. Hudes, Michael A. Carducci, Toni K. Choueiri, Peg Esper, Eric Jonasch, Rashmi Kumar, Kim Margolin, M. Dror Michaelson, Robert J. Motzer, Роберто Пили, Susan K. Roethke, Sandy Srinivas

I whakaputaina 2011

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
16

A Single-arm, Multicenter, Phase 2 Study of Lenvatinib Plus Everolimus in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma mā Thomas E. Hutson, M. Dror Michaelson, Timothy M. Kuzel, Neeraj Agarwal, Ana M. Molina, James J. Hsieh, Ulka N. Vaishampayan, Ran Xie, Urmi Bapat, Weifei Ye, Rohit Jain, Mayer Fishman

I whakaputaina 2021

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
17

Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma mā Charles S. Harmon, Samuel E. DePrimo, Robert A. Figlin, Gary R. Hudes, Thomas E. Hutson, M. Dror Michaelson, Sylvie Négrier, Sindy T. Kim, Xin Huang, James A. Williams, Tim Eisen, Robert J. Motzer

I whakaputaina 2013

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
18

Sunitinib rechallenge in metastatic renal cell carcinoma patients mā Ivan Zama, Thomas E. Hutson, Paul Elson, James M. Cleary, Toni K. Choueiri, Daniel Y.C. Heng, Nikhil H. Ramaiya, M. Dror Michaelson, Jorge A. García, Jennifer J. Knox, Bernard Escudier, Brian I. Rini

I whakaputaina 2010

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
19

Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma mā Robert J. Motzer, Thomas E. Hutson, Piotr Tomczak, M. Dror Michaelson, Ronald M. Bukowski, Olivier Rixe, Stéphane Oudard, Sylvie Négrier, Cezary Szczylik, Sindy T. Kim, Isan Chen, Paul Bycott, Charles M. Baum, Robert A. Figlin

I whakaputaina 2007

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
20

Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial mā Toni K. Choueiri, Susan Halabi, Ben L. Sanford, Olwen Hahn, M. Dror Michaelson, Meghara Walsh, Darren R. Feldman, Thomas Olencki, Joel Picus, Eric J. Small, Shaker R. Dakhil, Daniel J. George, Michael J. Morris

I whakaputaina 2017

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i: